NEW ISPOR Europe 2026 Session Explorer - Build Your Schedule →

The Accidental FX Trader: How United States MFN Pricing Reshapes Global Launch Strategy and Access

EntityRisk Co-Founder and CEO Neal Masia, PhD, will speak in this Fast Facts session on how US Most-Favored-Nation (MFN) pricing reaches beyond US drug prices, reshaping global launch strategy and patient access. Joined by panelists from GSK and Insights & Impact, Neal will explore the “Accidental FX Trader” dynamic: how currency swings and conversion rules create US price-benchmark risks that traditional foreign exchange strategies can’t hedge against.

Upcoming: Let's meet in Vienna?

Join EntityRisk and industry leaders for a discussion on how HEOR and Market Access professionals are navigating the evolving policy, access, and value landscapes.

About EntityRisk

EntityRisk integrates globally renowned health economics and policy expertise with PROVEN™, our advanced modelling software, to predict health outcomes, identify maximum value-based pricing, and substantiate evidence-generation investments.

10 of the Top 20 Biopharma Companies work with EntityRisk to navigate the shifting policy landscape and confidently choose and defend justifiable prices, inform evidence investments, and communicate and win on value.

10 / 20

Top Biopharma Companies

1,300+

Quality Checks

5

ML Modules